Nefopam pharmacokinetics in patients with end-stage renal disease

Anesthesia and Analgesia

Volumn 111, Issue 5, 2010, Pages 1146-1153

  Mimoz, Olivier ^a,b,c   Chauvet, Stéphane ^a   Grégoire, Nicolas ^b,c   Marchand, Sandrine ^a,b,c   Le Guern, Marie Emmanuelle ^d   Saleh, Ashraf ^d   Couet, William ^a,b,c   Debaene, Bertrand ^a,b,c   Levy, René H ^e  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE POITIERS   (France)

^d Service de Pharmacologie   (France)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DESMETHYLNEFOPAM; NEFOPAM; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ANESTHETIC RECOVERY; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEMOGRAPHY; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; FEMALE; GENERAL ANESTHESIA; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

EID: 78149462315     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181f33488     Document Type: Article

References (20)

1. Hasselström J, Berg U, Lofgren A, Säwe J. Long lasting respiratory depression induced by morphine-6-glucuronide. Brit J Clin Pharmacol 1989;27:515-8
2. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28:497-504
3. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1980;19:249-67
4. Mimoz O, Incagnoli P, Josse C, Gillon MC, Kuhlman L, Mirand A, Soilleux H, Fletcher D. Analgesic efficacy and safety of nefopam vs propacetamol following hepatic resection. Anaesthesia 2000;56:520-5
5. Kapfer B, Alfonsi P, Guignard B, Sessler DI, Chauvin M. Nefopam and ketamine comparably enhance postoperative analgesia. Anesth Analg 2005;100:169-74
6. Kehlet H, Werner M, Perkins F. Balanced analgesia: what is it and what are its advantages in postoperative pain? Drugs 1999;58:793-7
7. Bhatt AM, Pleuvry BJ, Maddison SE. Respiratory and metabolic effects of oral nefopam in human volunteers. Brit J Clin Pharmacol 1981;11:209-11
8. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intens Care 2005;33:311-22
9. Aymard G, Warot D, Démolis P, Giudicelli JF, Lechat P, Lechat P, Le Guern ME, Alquier C, Diquet B. Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteers. Pharmacol Toxicol 2003; 92:279-86
10. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83:898-903
11. Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001;12:326-32
12. Leblond FA, Petrucci M, Dubé P, Bernier G, Bonnardeaux A, Pichette V. Down-regulation of intestinal cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2002;13:1579-85
13. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
14. Rowland M, Tozer TN. Clinical Pharmacokinetics. Concepts and Applications. Philadelphia: Lea & Febiger, 1989
15. Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Brit J Pharmacol 2005;144:1067-77
16. Michaud J, Naud J, Chouinard J, Désy F, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2006;17:3041-8
17. Korashy HM, Elbekai RH, El-Kadi AOS. Effects of renal diseases on the regulation and expression of renal and hepatic drugmetabolizing enzymes: a review. Xenobiotica 2004;34:1-29
18. Lindup WE, Henderson SJ, Barker CE. Drug binding in renal disease. Plasma binding of drugs. In: Belpaire F, Bogaert M, Tillement JP, Verbeeck E, eds. Plasma Binding of Drugs and Its Consequences. Ghent: Academia Press, 1991:103-20
19. Lindup WE, Bishop KA, Collier R. Drug-binding defect of uraemic plasma: contribution of endogenous binding inhibitors. In: Tillement JP, Lindenlaub E. Protein Binding and Drug Transport. Stuttgart: Schattauer Verlag, 1986:399-414
20. Evans MS, Lysakowski C, Tramer MR. Nefopam for the prevention of postoperative pain: quantitative systematic review Br J Anaesth 2008;101:610-7